Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition

被引:2
|
作者
Li, Yanhui [1 ]
Ang, Mei San [2 ]
Yee, Jie Yin [2 ]
See, Yuen Mei [2 ]
Lee, Jimmy [1 ,3 ,4 ]
机构
[1] Inst Mental Hlth, Singapore, Singapore
[2] Inst Mental Hlth, Res Div, Singapore, Singapore
[3] Inst Mental Hlth, Dept Psychosis, Hougang, Singapore
[4] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore
来源
FRONTIERS IN PSYCHIATRY | 2024年 / 15卷
基金
英国医学研究理事会;
关键词
treatment-resistant schizophrenia; functioning; negative symptoms; social anhedonia; neurocognition; VOCATIONAL-REHABILITATION; CLINICAL PREDICTORS; DISABILITY; COGNITION; DETERMINANTS; 1ST-EPISODE; EMPLOYMENT; DISORDER; OUTCOMES;
D O I
10.3389/fpsyt.2024.1444843
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction Predictors of functioning are well-studied in schizophrenia, but much less so in treatment-resistant schizophrenia (TRS). In this study, we aim to investigate contributions of schizophrenia symptom domains and neurocognition to predict functioning in a TRS population (n = 146).Methods Participants were assessed on the Positive and Negative Syndrome Scale (PANSS), to calculate scores for five symptom factors (Positive, Negative, Cognitive, Depressive and Hostility) and two negative symptom constructs (Diminished Expressivity (DE), and Social Anhedonia (SA) as part of the Motivation and Pleasure-related dimension), based on a previously validated model, modified in accordance with EPA guidelines on negative symptoms assessment. Neurocognition was assessed with symbol coding and digit sequencing tasks from the Brief Assessment of Cognition in Schizophrenia (BACS). Functioning was assessed with the Social and Occupational Functioning Assessment Scale (SOFAS), employment status and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Multiple regression analyses were performed on psychopathology scores and BACS scores against all three measures of functioning, controlling for age and sex. For WHODAS, regression with PANSS scores of significant symptom factors were also performed.Results A lower severity of negative symptoms in the SA dimension was the strongest predictor of higher functioning across all three functioning measures. Neurocognition, in particular processing speed and attention assessed on the symbol coding task, predicted employment. A lower severity of somatic concerns and depressive symptoms was associated with lesser self-reported disability on WHODAS.Discussion This study represents a first attempt at elucidating significant predictors of functioning in TRS. We highlight negative symptoms and neurocognition as important treatment targets to improve functioning in TRS, consistent with previous studies in general schizophrenia.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS)
    Goldring, Abraham
    Borne, Sophia
    Hefner, Amanda
    Thanju, Amod
    Khan, Anzalee
    Lindenmayer, Jean-Pierre
    SCHIZOPHRENIA RESEARCH, 2020, 224 : 159 - 166
  • [32] The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia
    Quinlan, Thomas
    Roesch, Scott
    Granholm, Eric
    SCHIZOPHRENIA RESEARCH, 2014, 157 (1-3) : 182 - 189
  • [33] Combination of clozapine, cariprazine and fluoxetine in treatment-resistant schizophrenia patient with prominent negative symptoms: A Case report
    Everte, I.
    Pamse-Romane, A.
    Taube, M.
    EUROPEAN PSYCHIATRY, 2022, 65 : S781 - S781
  • [34] Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms
    Yang, Zixu
    Lee, Soon Hong
    Abdul Rashid, Nur Amirah
    See, Yuen Mei
    Dauwels, Justin
    Tan, Bhing Leet
    Lee, Jimmy
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [35] The longitudinal structure of negative symptoms in treatment resistant schizophrenia
    Wolpe, Noham
    Vituri, Aya
    Jones, Peter B.
    Shahar, Moni
    Fernandez-Egea, Emilio
    COMPREHENSIVE PSYCHIATRY, 2024, 128
  • [36] Prevalence and predictors of treatment-resistant schizophrenia in a tertiary hospital in Northeast Brazil
    Soares, Douglas de Sousa
    Carvalho, Danyelle Rolim
    Ribeiro, Mellanie Dellylah Trinta
    Diniz, Elton Jorge Bessa
    Neto, Alcides Ferreira Rego
    TRENDS IN PSYCHIATRY AND PSYCHOTHERAPY, 2021, 43 (04) : 270 - 277
  • [37] Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia
    Rajkumar, Anto P.
    Poonkuzhali, Balasubramanian
    Kuruvilla, Anju
    Jacob, Molly
    Jacob, Kuruthukulangara S.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (01) : 50 - 56
  • [38] Clozapine for Treatment-Resistant Schizophrenia
    Manu, Peter
    Grudnikoff, Eugene
    AMERICAN JOURNAL OF THERAPEUTICS, 2016, 23 (05) : E1133 - E1134
  • [39] Handbook of treatment-resistant schizophrenia
    Volavka, J.
    ACTA PSYCHIATRICA SCANDINAVICA, 2013, 128 (01) : 102 - 102
  • [40] Pharmacotherapy for treatment-resistant schizophrenia
    Mcilwain, Meghan E.
    Harrison, Jeff
    Wheeler, Amanda J.
    Russell, Bruce R.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 135 - 149